These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26107112)

  • 1. Recent prospective of surface engineered Nanoparticles in the management of Neurodegenerative disorders.
    Singh D; Kapahi H; Rashid M; Prakash A; Majeed AB; Mishra N
    Artif Cells Nanomed Biotechnol; 2016 May; 44(3):780-91. PubMed ID: 26107112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.
    Nguyen KT; Pham MN; Vo TV; Duan W; Tran PH; Tran TT
    Curr Drug Metab; 2017; 18(9):786-797. PubMed ID: 28124594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upconversion Nanoparticle-Based Strategy for Crossing the Blood-Brain Barrier to Treat the Central Nervous System Disease.
    Fu L; Chung R; Shi B
    Methods Mol Biol; 2019; 2054():263-282. PubMed ID: 31482461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.
    Rajpoot K
    Curr Drug Targets; 2020; 21(8):819-836. PubMed ID: 31906836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
    Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnological applications for the treatment of neurodegenerative disorders.
    Modi G; Pillay V; Choonara YE; Ndesendo VM; du Toit LC; Naidoo D
    Prog Neurobiol; 2009 Aug; 88(4):272-85. PubMed ID: 19486920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Strategies for Brain Drug Delivery.
    Dong X
    Theranostics; 2018; 8(6):1481-1493. PubMed ID: 29556336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of neurodegenerative disorders employing nanotechnology.
    Modi G; Pillay V; Choonara YE
    Ann N Y Acad Sci; 2010 Jan; 1184():154-72. PubMed ID: 20146696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport of drugs across the blood-brain barrier by nanoparticles.
    Wohlfart S; Gelperina S; Kreuter J
    J Control Release; 2012 Jul; 161(2):264-73. PubMed ID: 21872624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
    Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
    Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.
    Ruiz-López E; Schuhmacher AJ
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Lipid Nanoparticles and its Surface Modification in Reaching the Brain: An Approach for Neurodegenerative Diseases Treatment.
    Hernando S; Pedraz JL; Igartua M; Hernandez RM
    Curr Drug Deliv; 2018; 15(9):1218-1220. PubMed ID: 29745334
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
    Spuch C; Saida O; Navarro C
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.
    Pehlivan SB
    Pharm Res; 2013 Oct; 30(10):2499-511. PubMed ID: 23959851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain drug delivery systems for neurodegenerative disorders.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2388-402. PubMed ID: 23016644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
    Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
    Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
    Md S; Mustafa G; Baboota S; Ali J
    Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving drug delivery technology for treating neurodegenerative diseases.
    Choonara YE; Kumar P; Modi G; Pillay V
    Expert Opin Drug Deliv; 2016 Jul; 13(7):1029-43. PubMed ID: 26967508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.